三阴性乳腺癌(TNBC)由于其侵袭性,提出了一个重要的全球健康问题,高死亡率和有限的治疗选择,强调迫切需要有针对性的治疗。波维菌素,一种生物活性真菌次级代谢产物,具有显著的抗癌潜力,尽管其在癌细胞中的分子靶标仍未被探索。这项研究调查了白僵素可能的分子靶标及其在TNBC细胞中的治疗见解。使用分子对接和MD模拟进行的计算机模拟研究预测了白僵素的分子靶标。确定的目标包括MRP-1(ABCC1),HDAC-1,HDAC-2,LCK和SYK,平均结合能为-90.1,-44.3,-72.1,-105和-60.8KJ/mol,分别,暗示其在逆转耐药性方面的多方面作用,抑制表观遗传调节剂和致癌酪氨酸激酶。Beauvericin显著降低了MDA-MB-231和MDA-MB-468细胞的活力,IC50浓度为4.4和3.9µM,同时将细胞内ROS提高9.0倍和7.9倍,分别。随后在TNBC细胞中线粒体跨膜电位的降低,已经证实了氧化应激的诱导,导致细胞凋亡,通过流式细胞仪分析观察到。Beauvericin还将细胞周期阻滞在G1期,并损害了TNBC细胞的球状体形成和克隆扩增能力。球状体的生存力在白僵素治疗后降低,在MDA-MB-468和MDA-MB-231细胞中表现出10.3和6.2µM的IC50浓度,分别。总之,通过可能抑制MRP-1(ABCC1),白藜芦醇已证明了对TNBC细胞的有希望的治疗潜力,HDAC-1、HDAC-2、LCK和SYK。
Triple negative breast cancer (TNBC) presents a significant global health concern due to its aggressive nature, high mortality rate and limited treatment options, highlighting the urgent need for targeted therapies.
Beauvericin, a bioactive fungal secondary metabolite, possess significant anticancer potential, although its molecular targets in cancer cells remain unexplored. This study has investigated possible molecular targets of
beauvericin and its therapeutic insights in TNBC cells. In silico studies using molecular docking and MD simulation predicted the molecular targets of
beauvericin. The identified targets included MRP-1 (ABCC1), HDAC-1, HDAC-2, LCK and SYK with average binding energy of -90.1, -44.3, -72.1, -105 and -60.8 KJ/mol, respectively, implying its multifaceted roles in reversing drug resistance, inhibiting epigenetic modulators and oncogenic tyrosine kinases. Beauvericin has significantly reduced the viability of MDA-MB-231 and MDA-MB-468 cells, with IC50 concentrations of 4.4 and 3.9 µM, while concurrently elevating the intracellular ROS by 9.0 and 7.9 folds, respectively. Subsequent reduction of mitochondrial transmembrane potential in TNBC cells, has confirmed the induction of oxidative stress, leading to apoptotic cell death, as observed by flow cytometric analyses. Beauvericin has also arrested cell cycle at G1-phase and impaired the spheroid formation and clonal expansion abilities of TNBC cells. The viability of spheroids was reduced upon
beauvericin treatment, exhibiting IC50 concentrations of 10.3 and 6.2 µM in MDA-MB-468 and MDA-MB-231 cells, respectively. In conclusion,
beauvericin has demonstrated promising therapeutic potential against TNBC cells through possible inhibition of MRP-1 (ABCC1), HDAC-1, HDAC-2, LCK and SYK.